• Innorini Pte Ltd appointed as exclusive licensee for Nasodine products in Singapore, Malaysia, Brunei, and Mauritius
• New agreement expected to significantly reduce Firebrick's marketing expenses in FY26
• Expanded distribution to open up new markets for Nasodine products

Firebrick Pharma Ltd (ASX:FRE) has announced the execution of a License and Distribution Agreement with Innorini Pte Ltd, granting the company exclusive rights to distribute, promote, and sell Nasodine® Nasal Spray and all future Nasodine brand products in Singapore, Malaysia, Brunei, and Mauritius. Innorini has been an existing partner of Firebrick, having previously signed a Marketing Representation Agreement for the marketing of Nasodine Nasal Spray to healthcare professionals in Singapore. The new agreement replaces the previous MRA and expands Innorini's role to include all distribution, promotion, and sale of Nasodine products in the four countries. Importantly, the agreement stipulates that Innorini will bear all marketing costs in the territory from January 1, 2026, which is expected to significantly reduce Firebrick's advertising and promotion expenditure compared to FY25. The agreement also provides Innorini with the right to manufacture Nasodine products anywhere in the territory, which will provide for future supply flexibility and reduced manufacturing, shipping, and other costs associated with importing products from Australia. Firebrick's Executive Chairman, Dr. Peter Molloy, expressed his confidence in Innorini as an excellent partner and the company's excitement to expand the marketing of Nasodine to new markets where there is a clear need for effective, science-driven healthcare products.

The expanded distribution agreement with Innorini is expected to open up new markets for Firebrick's Nasodine products and significantly reduce the company's marketing expenses in FY26 and beyond.